Karian Pharmaceuticals

Karian Pharmaceuticals operates as a rapidly expanding pharmaceutical firm based in Greece. The individuals within the company are committed to working with a strong sense of accountability, following a contemporary and dynamic business model, with a focus on meeting the requirements of the medical community and patients. An aria represents an intricate and polished segment in an opera that is typically reserved for the top performer. Just as an aria boldly progresses the storyline, at Aria Pharmaceuticals, we are dedicated to advancing innovative breakthroughs in medicine. We firmly believe in the work we undertake for patients who are in need. The name exemplifies the artistry and intricacy that characterizes our approach to medicine from conception to FDA approval in a manner that is scientifically robust. Arixa Pharmaceuticals™ is in the process of developing oral antibiotics for resistant Gram-negative infections, which are urgently required. Our primary program involves an oral prodrug of Avibactam®, a broad-spectrum beta-lactamase inhibitor that has recently been approved by the FDA. We have tackled and resolved the challenges in medicinal chemistry that complicate the prodrug design of this category of compounds and have obtained extensive patent protection for the composition of matter from the US Patent & Trademark Office. Our prodrug AV-006/ARX-1796 recently demonstrated positive outcomes in its initial human clinical trial. Riparian Pharmaceuticals, Inc., is a privately owned biotechnology company established to uncover drug targets and therapeutics that affect endothelial dysfunction and vascular inflammation. The company's therapeutics are focused on novel vasoprotective pathways to address prevalent and serious rare vascular diseases at an early stage, allowing physicians to achieve improved patient results. Riparian has secured $6M in combined investments and research services from Viva Biotech Incubator and JMCR Partners, as well as backing from research foundations including the National Institutes of Health and the Massachusetts Life Science Center.